Welcome to our dedicated page for Biophytis SA SEC filings (Ticker: BPTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Biophytis SA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Biophytis SA's regulatory disclosures and financial reporting.
Biophytis S.A. filed a report noting that it has issued a press release unveiling its Phase 3 sarcopenia trial strategy for its investigational product BIO101 in Europe and Asia. The filing mainly serves to furnish this press release to investors as an exhibit.
Biophytis S.A. reports that it has obtained authorization from the European Medicines Agency (EMA) to launch a Phase 2 clinical trial in obesity. The company communicated this development through a press release, which is included as an exhibit to the report for additional detail.
Biophytis S.A. filed a Form 6-K to share a new clinical development update. The company reported that it issued a press release on September 1, 2025 unveiling its Phase-2 obesity trial strategy using BIO101 in Europe and Brazil.
The press release is attached as Exhibit 99.1 to the report, providing more detail on how Biophytis plans to advance BIO101 in obesity through this Phase-2 program in those regions.
Biophytis S.A. reported that it has received approval from the European Medicines Agency (EMA) and Belgian regulators to start a Phase 3 clinical trial in sarcopenia, a muscle loss condition often linked to aging. This clearance allows the company to begin late-stage testing of its sarcopenia treatment candidate in Europe, an important step in evaluating whether the therapy can demonstrate meaningful clinical benefit in a larger patient population.
The update was communicated through a press release dated August 28, 2025, which is attached to the report as an exhibit.
Biophytis S.A. (ticker: BPTS) filed a Form 6-K on June 24, 2025, to alert investors that, on June 19, 2025, it issued a press release announcing the temporary suspension of trading of its shares. The filing attaches the press release as Exhibit 99.1. No further details—such as the duration, cause, or expected resolution of the suspension—are provided in the submission. The only signatory is Chairman and CEO Stanislas Veillet. Because the document offers no financial statements, earnings data, or transaction details, its sole material disclosure is the trading halt.